Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc., a pioneering biopharmaceutical company based in the United States, focuses on developing innovative treatments for food allergies. Founded in 2011, Aimmune has made significant strides in the industry, particularly with its flagship product, Palforzia, which is the first FDA-approved therapy for peanut allergy. This groundbreaking treatment offers a unique approach to desensitising patients, setting Aimmune apart in the competitive landscape of allergy therapeutics.
With its headquarters in Brisbane, California, Aimmune operates primarily in North America and has established a strong market position through its commitment to research and development. The company’s dedication to advancing food allergy treatments has garnered recognition, positioning Aimmune as a leader in the biopharmaceutical sector.
+61 vs industry average
Aimmune Therapeutics, Inc.’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Aimmune Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Aimmune Therapeutics, Inc. yet.
Aimmune Therapeutics, Inc.'s reported carbon emissions
Aimmune Therapeutics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Nestlé S.A., Aimmune's climate commitments and reduction initiatives are influenced by its parent company's sustainability strategies.
While no direct emissions figures are provided, Aimmune is aligned with Nestlé's climate initiatives, which include targets set through the Science Based Targets initiative (SBTi) and participation in various sustainability frameworks such as CDP and RE100. These initiatives aim to significantly reduce greenhouse gas emissions across all scopes, although specific reduction targets for Aimmune have not been disclosed.
As part of its commitment to sustainability, Aimmune is expected to adhere to Nestlé's overarching climate goals, which focus on achieving net-zero emissions and promoting responsible sourcing and production practices. However, without specific emissions data or reduction targets, the precise impact of Aimmune's efforts remains unclear.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Aimmune Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Aimmune Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Nestlé S.A.
Carbon Disclosure Project
Inherited from Nestlé S.A.
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Nestlé S.A.
RE 100
Inherited from Nestlé S.A.
Climate Action 100
Inherited from Nestlé S.A.Emissions comparison with industry peers
View similar organisations
Aimmune Therapeutics, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project